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Abstract 
Background: There is a demand for a highly sensitive and specific point‑of care test to detect acute myocardial 
infarction (AMI). It is unclear if a high‑sensitivity troponin assay will have enough discriminative power to become a 
decision support in primary care. The aim of this study was to evaluate a high‑sensitivity troponin T assay performed 
in three primary health care centres in southeast Sweden and to compare the outcome with a point‑of‑care troponin 
T test.
Methods: This study included 115 patients who consulted their general practitioner for chest pain, dyspnoea on 
exertion, unexplained weakness and/or fatigue in the last 7 days. Troponin T was analysed by a point‑of‑care test and 
a high‑sensitivity method together with N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP) and creatinine. All 
patients were checked for AMI or unstable angina (UA) within 30 days of study enrolment. Univariate and multivariate 
logistic regression was carried out to examine possible connections between troponin T ≥ 15 ng/L, clinical variables 
and laboratory findings at baseline. In addition, 21 patients with troponin T ≥ 15 ng/L and no signs of AMI or UA were 
followed up for 2–3 years.
Results: Three patients were diagnosed with AMI and three with UA. At the ≥ 15 ng/L cut‑off, the troponin T method 
had 100% sensitivity, 75% specificity for AMI and a positive predictive value of 10%. The troponin T point‑of‑care test 
missed one case of AMI and the detection limit was 50 ng/L. Troponin T ≥ 15 ng/L was correlated to age ≥65 years 
(odds ratio (OR), 10.9 95% CI 2.28–51.8) and NT‑proBNP in accordance with heart failure (OR 8.62 95% CI 1.61–46.1). 
Fourteen of the 21 patients, without signs of AMI or UA at baseline, still had increased troponin T at follow‑up after 
2–3 years.
Conclusions: A high‑sensitivity troponin T assay could become useful in primary care as a point‑of‑care test for 
patients <65 years. For patients older than 65–70 years, a higher decision limit than ≥15 ng/L should be considered 
and used in conjunction with clinical parameters and possibly with NT‑proBNP.
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Background
Chest pain is a challenge for the general practitioner (GP) 
and is a symptom found in 1–3% of primary care patients 
[1, 2]. Chest pain can be caused by a wide range of ill-
nesses and most are not of cardiac origin. Chest pain is 
due to ischaemic heart disease in 10–18% of cases, acute 
myocardial infarction (AMI) in 2–4% of cases, or unsta-
ble angina (UA) [3, 4], all of which require immedi-
ate attention. Cardiac troponin T (cTnT) is a biomarker 
specific for cardiac injury and an increased plasma con-
centration together with a dynamic course is one of the 
most important criteria for AMI used in hospital care 
[5]. Some authors have suggested that measurement of 
cTnT could also help to assess patients with chest pain in 
primary care [6–10]. In a previous study, we found that 
the use of a commercially available point-of-care test 
(POCT) for cTnT may reduce emergency referrals but at 
the cost of a number of missed cases of AMI or UA [11]. 
We found that the sensitivity of the POCT-cTnT test to 
diagnose an AMI was 67% and for AMI and UA together, 
only 29%, using the current detection level of 30  ng/L. 
This emphasizes the need for a more sensitive POCT 
troponin assay in primary care. However, there are no 
POCTs for high-sensitivity troponin T (hs-cTnT) avail-
able. The use of a potential hs-cTnT or cTnI test in pri-
mary care has some pitfalls. If the blood sample is drawn 
too early in the course of an AMI, the troponin value may 
still be below the decision limit and an AMI or UA may 
be overlooked. There is also a demand for a method with 
high specificity to avoid results above the decision level 
with no AMI. This is particularly important in primary 
care, because AMI is more often not the cause of chest 
pain in this population [3, 4]. Poor specificity of hs-cTnT 
has been an issue in several studies and falsely increased 
cTnT is common in older patients with decreased renal 
function [5, 12].
The aim of this study was to evaluate an hs-cTnT assay 
applied to a primary care population with chest pain and 
to compare the outcome with POCT-cTnT. Another aim 
was to investigate the persistence of hs-cTnT above the 
cut-off limit of 15 ng/L after 2–3 years in patients with no 
evidence of acute coronary syndrome.
Methods
Study design
An observational prospective study with follow-up 
was performed between May 2009 and January 2011 in 
3 primary health care (PHC) centres in the county of 
Östergötland, situated in southeast Sweden. In the study 
published in 2013 by Nilsson et  al. [11], samples from 
128 patients with chest pain were investigated by POCT-
cTnT. However, present study includes samples from 115 
of these patients because in 13 cases the blood samples 
were lost (four due to a broken freezer, nine due to other 
administrative failures). One of these lost cases was diag-
nosed as UA.
Data collection
In all three PHC centres, according to normal routines, 
all patients were given an appointment with their GP 
after calling the PHC centre and talking to a nurse; the 
nurse included all eligible patients according to the fol-
lowing inclusion criteria: chest pain, dyspnoea on exer-
tion, unexplained weakness and/or fatigue commencing 
or becoming aggravated during the last 7  days; age 
≥35  years. Exclusion criteria were as follows: patients 
with symptoms severely affecting their general condition; 
probable causes of chest pain other than cardiac, accord-
ing to a nurse’s telephone assessment, e.g. costal fracture 
or gastroesophageal reflux. In addition to the patients 
included by the nurses, the GPs were asked to include eli-
gible patients in conjunction with consultations.
Management of the patients was noted by the GPs on 
the case report form developed for the study. The follow-
ing variables were used: current smoker; ongoing smok-
ing or stopped less than 1 month ago; diabetes, on a diet 
or medication; hypertension, on medication currently or 
previously; hypercholesterolaemia, taking cholesterol-
lowering medication; angina pectoris, effort-related chest 
pain; previous AMI, previous diagnosis of myocardial 
infarction, also silent myocardial infarctions with obvi-
ous changes found on an electrocardiogram (ECG) or 
echocardiography; coronary revascularization, previous 
percutaneous coronary intervention or coronary artery 
bypass graft operation; stroke and heart failure, previ-
ously diagnosed; aortic valve disease, insufficiency or ste-
nosis of more than slight significance. A clinical diagnosis 
of renal failure was based on a plasma creatinine level of 
>200 µmol/L in men and >160 µmol/L in women. An ECG 
was registered and interpreted by the GPs in conjunction 
with their first assessment of each patient in the study.
The end point evaluation method is described elsewhere 
[11]. The cases of AMI and UA in the study were diag-
nosed in conjunction with the first visit. They could also be 
diagnosed within 30 days provided they were assessed as 
missed cases in primary care [11]. The diagnoses of AMI 
and UA were based on the current definitions [5].
Follow‑up of patients with hs‑cTnT levels above 15 ng/L 
but without signs of AMI or UA
Twenty-six patients had hs-cTnT levels above 15 ng/L but 
no evidence of AMI or UA within 30 days after drawing 
the blood sample. Three of the patients had died by the 
follow-up. The remaining 23 were invited for a follow-up 
examination. One patient declined due to advanced can-
cer and one had moved to another county in Sweden. The 
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remaining 21 accepted the invitation. The patients were 
asked to avoid physical exercise the day before the exami-
nation because earlier studies have shown that physical 
exercise or hard physical training can cause increased hs-
cTnT levels [13]. Follow-up was performed at the PHC 
centre where the patient had chosen to be listed. The 
time after inclusion in the study varied between 25 and 
42 months (average 34 months). In all 21 cases, the fol-
low-up was performed by the same researcher.
All patients were asked the same questions from a spe-
cial form that was produced exclusively for this study and 
the same procedure was used for everyone. Data on ECG, 
weight, height, body mass index, waist circumferences 
and blood pressure were collected. An ECG was regis-
tered and compared with the ECG that was performed at 
the start of the study. We searched for new findings, i.e. 
atrial fibrillation, ST elevation and pathologic q-waves. 
Blood pressure was taken from the right arm with the 
patient in a sitting position; patients rested for 5  min 
before the measurements were taken. Waist circumfer-
ence was measured with the patient in a standing position 
during exhalation. Blood samples were collected by veni-
puncture and sent for analysis of cholesterol, creatinine, 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
and hs-cTnT on the same day. The diagnosis of heart 
failure was based on impaired left ventricular function 
according to echocardiogram if performed earlier, and/
or by clinical findings. Ten of the patients had undergone 
echocardiogram from 8 years to 6 months before the fol-
low-up. At the consultation, the patients were asked about 
new symptoms since inclusion in the study, i.e. chest pain, 
dyspnoea, angina or exercise-related chest pain.
Analytical methods
Blood samples
Blood was collected by venipuncture in vacuum tubes 
containing separating gel and lithium heparin (4  mL; 
Greiner Bio-One, Frickenhausen, Germany) or separat-
ing gel and silica coagulation activator (4  mL; Greiner 
Bio-One). After resting for 30–60  min, the tubes were 
centrifuged at 2,400×g for 5  min. Aliquots of serum 
and plasma were stored initially at −20°C for less than 
1  month, after which the samples were transferred to 
−70°C and kept frozen until analysis.
POCT‑cTnT
Troponin T was measured on the POCT instrument 
Cobas h232 (Roche Diagnostics, Mannheim, Germany). 
The detection limit was 0.03 µg/L (30 ng/L) and all values 
>0.03 µg/L (>30 ng/L) were regarded as positive accord-
ing to the manufacturer’s recommendations. Further 
details about the method for POCT-cTnT are described 
elsewhere [11].
hs‑cTnT
Cardiac troponin T was measured in plasma by immu-
nochemical methods using detection based on lumines-
cence on a Cobas e602 instrument (Roche Diagnostics, 
Mannheim, Germany). The method used for cTnT was 
a highly sensitive method with a limit of detection of 
1 ng/L. A decision limit of ≥15 ng/L was used. This limit 
was based on the 99th percentile calculated for a healthy 
population, according to Roche [14]. The lot number of 
the reagent was 167,650 and of the calibrator 165,095. 
These are new revised lots. However, when patients were 
admitted to the hospital, the diagnosis was based on hs-
cTnT values measured by the old non-revised lots, which, 
according to Roche, have recently been found to produce 
low results in the interval 3–20 ng/L [15]. The coefficient 
of variation (CV) for a 2-month period was 2.9% (level 
24 ng/L) and 3.6% (level 1,600 ng/L) for hs-cTnT.
Other laboratory analyses
Creatinine was measured in plasma samples from all 
patients using a standardized method (Advia 1800; Sie-
mens Healthcare Diagnostics, Deerfield, IL, USA). The 
method was based on Jaffe reagent and contained a rate-
blanking measurement to compensate for interference 
from bilirubin and a correction for intercept due to pseu-
docreatinines. An estimated glomerular filtration rate 
(eGFR) was calculated based on the creatinine level using 
the modification of diet in renal disease equation [16].
N-terminal pro B-type natriuretic peptide (NT-
proBNP) was measured in plasma samples from all 
patients at baseline and at follow-up. Analysis was per-
formed on a Cobas e602 instrument (Roche Diagnostics). 
This assay is based on immunochemistry with 2 monoclo-
nal antibodies and electrochemiluminescence detection.
Cholesterol was measured in plasma samples from 
patients at the follow-up. Analysis was performed on an 
Advia 1800 instrument (Siemens Healthcare Diagnostics) 
by a method with reagent and calibrator from the same 
company. The reference ranges used were 3.3–6.9 mmol/L 
(31–50 years) and 3.9–7.8 mmol/L (>50 years) [17].
Statistical analysis
At baseline and at the follow-up, possible differences 
regarding demographics (age, gender), risk factors (smok-
ing habits, diabetes, hypertension and hypercholesterol-
aemia), cardiovascular disease (angina pectoris, previous 
AMI, coronary revascularization, stroke, heart failure and 
aortic valve disease), ECG findings (sinus rhythm, atrial 
fibrillation), and laboratory findings (renal failure, eGFR, 
NT-proBNP, and potential causes of increased hs-cTnT) 
between patients with hs-cTnT levels above or below 
15  ng/L were tested with the Pearson χ2 test and the 
Fisher exact test if the data were discrete. Continuous data 
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were analysed with the Student t test if approximately 
normally distributed, otherwise the non-parametric 
Mann–Whitney test was used. Univariate and multivari-
ate logistic regression was carried out to examine pos-
sible differences between high and low hs-cTnT levels at 
baseline regarding all the variables, except renal failure 
and potential causes of increased hs-cTnT (due to small 
numbers). In the logistic regression models, the continu-
ous variable NT-proBNP was transformed into a dichoto-
mous variable according to age and a high likelihood of 
heart failure, i.e. >450  ng/L (<50  years), >900  ng/L (50–
75 years) and >1,800 ng/L (>75 years) [18].
Age was also transformed into a dichotomous vari-
able; >65  years according to the results for emergency 
room patients reported by Hammarsten et  al. [12] and 
our own findings (Figure  1). Data on angina pectoris, 
AMI and percutaneous coronary intervention/coronary 
artery bypass graft were combined into one variable due 
to small numbers. All variables were adjusted for sex and 
age in the univariate models, and those who had a P value 
<0.10 were considered for the multivariate model. A P 
value <0.05 was considered statistically significant.
Ethics
The Regional Ethical Review Board in Linköping, Sweden 
(Dnr M101-09, T98-09 and Dnr 2010/211-32) approved 
the study. Written informed consent was obtained from 
all patients before enrolment in the study.
Results
One hundred and fifteen patients were enrolled in the 
study. Only three had AMI and three had UA. Thirty-one 
patients had hs-cTnT >15 ng/L. The group with hs-cTnT 
>15 ng/L was on average 15 years older, more often male 
and more often diagnosed with heart failure or atrial 
fibrillation. They also had lower eGFR and higher NT-
proBNP compared with those with hs-cTnT <15  ng/L 
(Table 1). hs-cTnT analysis had a much higher sensitivity 
Table 1 Clinical characteristics of 115 patients with chest pain in relation to the level of hs-cTnT
Values are presented as mean ± SD or number (%).
a Not applicable.
b >450 ng/L (<50 years), >900 ng/L (50–75 years), and >1,800 ng/L (>75 years).
c Hypertrophic cardiomyopathy or amyloidosis








 Age, years 65 ± 14 61 ± 13 76 ± 11 <0.001
 Sex, male 66 (57) 41 (49) 25 (81) 0.003
Risk factors
 Current smokers 15 (13) 12 (14) 3 (10) 0.756
 Diabetes 17 (15) 9 (11) 8 (26) 0.072
 Hypertension 42 (37) 25 (30) 17 (55) 0.017
 Hypercholesterolaemia 34 (30) 22 (26) 12 (39) 0.250
Cardiovascular disease
 Angina pectoris 20 (17) 11 (13) 9 (29) 0.056
 Previous AMI 19 (17) 12 (14) 7 (23) 0.395
 Coronary revascularization 14 (12) 10 (12) 4 (13) 1.000
 Stroke 4 (3.5) 3 (3.6) 1 (3.2) 1.000
 Heart failure 11 (10) 4 (4.8) 7 (23) 0.008
 Aortic valve disease 4 (3.5) 1 (1.2) 3 (9.7) 0.059
 Renal failure clinically diagnosed 1 (0.9) 0 (0) 1 (3.2) 0.270
ECG findings
 Atrial fibrillation 12 (10) 3 (3.6) 9 (29) <0.001
Laboratory findings
 POCT‑cTnT >30 ng/L 4 0 4 NAa
 eGFR, mL/min 68 ± 16 71 ± 15 59 ± 15 <0.001
 NT‑proBNPb 13 (11) 2 (2.4) 11 (37) <0.001
Other
 Potential causes of increased troponin T in the 
absence of overt ischaemic heart disease, n (%)c
1 (0.9) 1 (1.2) 0 (0) 1.000
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for finding AMI (100 vs 67%) and the combination of 
AMI and UA (83 vs 33%) compared with POCT-cTnT. 
However, this increase in sensitivity was at the expense 
of greatly reduced specificity, from 98% to 75–76%. The 
positive predictive value (PPV) was only 10% for AMI 
and 16% for the combination of AMI and UA (Table 2). 
Besides a diagnosis of AMI or UA (odds ratio (OR) 53.8 
95% CI 3.37–859), the multivariate analysis showed that 
age at least 65 years (OR 10.9 95% CI 2.28–51.8) and an 
NT-proBNP value in accordance with heart failure (OR 
8.62 95% CI 1.61–46.1) were significantly related to hs-
cTnT >15  ng/L (Table  3). Atrial fibrillation and eGFR 
showed a significant association with the level of hs-cTnT 
in the clinical characteristics (Table 1), as well as in the 
logistic univariate models (not shown). The significance 
disappeared after adjusting these variables for age and 
sex. They were therefore excluded from the final model, 
although the P values (0.073 and 0.079, respectively) indi-
cated a tendency to association with the level of hs-cTnT. 
The time between onset of symptoms and examination 
by the GP and blood sampling was at least 10 h. Figure 1 
shows the individual values of hs-cTnT in relation to age. 
It is also clear that samples with hs-cTnT values between 
30 and 50  ng/L failed to give positive values on the 
POCT-cTnT instrument (Cobas h232) in contradiction 
to the manufacturer’s specifications (a detection limit of 
30 ng/L).
Follow‑up of patients with hs‑cTnT levels >15 ng/L 
but without signs of AMI or UA
Twenty-four patients with hs-cTnT ≥15  ng/L without 
any signs of AMI or UA were enrolled in the follow-
up after 2–3  years. Three of these patients had died, 
all men, at the ages of 86, 89 and 93  years (two died of 
heart failure and one in cardiac arrest), leaving 16 men 
and 5 women in the remaining group to be investigated. 
These 21 patients had no anamnestic or ECG signs of 
AMI during the follow-up. Eighteen of these patients 
had a diagnosis of hypertension. However, according to 
measurements, their blood pressure was well regulated 
with a mean value of 120 mm Hg systolic and 70 mm Hg 
diastolic. All patients had cholesterol values below the 
reference limit (Table 4). In seven patients, hs-cTnT was 
normalized but in 14 cases hs-cTnT was still >15  ng/L 
(Table  4). The group with persistent increased hs-cTnT 
was on average 8 years older, had lower eGFR and higher 
NT-proBNP compared with the group with normalized 
hs-cTnT (Table 4). Atrial fibrillation was more common 
in the group with hs-cTnT >15 ng/L although not statisti-
cally significant.
Table 2 Diagnostic accuracy of point-of-care test for cardiac troponin T (POCT-cTnT) and high sensitivity cardiac troponin 
T (hs-cTnT) to find acute myocardial infarction (AMI) and the combination of AMI or unstable angina (UA)
Decision limit: POCT-cTnT >30 ng/L, hs-cTnT >15 ng/L.
Sensitivity Specificity PPV NPV
n % n % n % n %
AMI
 POCT‑cTnT 2/3 67 110/112 98 2/4 50 110/111 99
 hs‑cTnT 3/3 100 84/112 75 3/31 10 84/84 100
AMI/UA
 POCT‑cTnT 2/6 33 107/109 98 2/4 50 107/111 96
 hs‑cTnT 5/6 83 83/109 76 5/31 16 83/84 99
Table 3 Odds ratios (OR) for 115 patients with chest pain to have hs-cTnT ≥15  ng/L using univariate and multivariate 
logistic regression
a >450 ng/L (<50 years), >900 ng/L (50–75 years), and >1,800 ng/L (>75 years).
Beta Standard error Wald Df P OR 95% confidence interval
Age (65 years or older) 2.39 0.80 8.95 1 0.003 10.9 2.28–51.8
Sex (male) 1.11 0.59 3.54 1 0.060 3.02 0.96–9.56
NT‑proBNPa 2.15 0.86 6.33 1 0.012 8.62 1.61–46.1
AMI or UA 3.99 1.41 7.94 1 0.005 53.8 3.37–859
Constant −3.89 0.85 21.0 1 0.000 0.02
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Discussion
A considerable number of patients consulting PHC have 
chest pain and other symptoms suggesting AMI or UA. 
The challenge to distinguish between heart disease and 
symptoms in the thoracic area due to other causes are 
well known amongst GPs.
The sensitivity for hs-cTnT to find AMI or the com-
bination of AMI and UA was 100 and 83%, respectively, 
i.e. substantially better than for POCT-cTnT. The speci-
ficity of hs-cTnT was lower compared with the POCT 
method, but was similar to the findings in a population 
with acute chest pain in the emergency department (ED) 
(75%). However, the PPV for AMI in our study was only 
10% compared with 63% in the ED [19]. This empha-
sizes the difficulty with interpreting hs-cTnT results in 
conjunction with outcome. In order to investigate if the 
diagnostic usability of hs-cTnT could be improved, we 
performed a multivariate analysis to evaluate other pos-
sible explanations for an increased hs-cTnT level. Age 
65 years or more was strongly correlated to a troponin T 
level ≥15  ng/L. This in accordance with the findings of 
Hammarsten et  al. [12] who found highly age-depend-
ent cTnT percentiles above a breaking point of around 
65 years in ED patients without conditions that increase 
cTnT. In accordance with our results, several authors 
have suggested that a higher decision limit must be con-
sidered for patients older than 65–70 years [12, 20, 21]. 
In our study, male sex was at the limit of significance 
(Table 3). Population-based studies on people of younger 
ages have shown higher cTnT values for men compared 
with women [14]. This has also been found in one study 
of ED patients older than 65  years [12]. However, some 
recent studies have failed to show gender differences at 
ages above 75  years [20, 21]. We also found that NT-
proBNP above a level in accordance with heart failure 
had a strong correlation to a cTnT level of ≥15  ng/L, 
whereas the clinical diagnosis of heart failure had not. It 
is well known that a diagnosis of heart failure based on 
clinical findings is very uncertain and patients are often 
managed without a confirming echocardiogram in PHC 
[22]. Hence, there may have been some undiagnosed 
cases of heart failure in the study. Renal function was not 
correlated to increased hs-cTnT according to the multi-
variate analyses, probably explained by the well-known 
influence of age on renal function.
A dynamic course of the cTnT level is an important 
diagnostic criteria for AMI [5]. However, a single hs-
cTnT value could serve as decision support when safely 
ruling out AMI in patients with recent onset of symp-
toms or to diagnose AMI or UA with diffuse symptoms 
Figure 1 hs‑cTnT values for 112 patients with chest pain in relation to age. The results from Cobas h232 were noted as positive in 4 cases (i.e. 
>30 ng/L). Three of these results are not shown in the figure because their hs‑cTnT values were 204, 220 and 520 ng/L. Two of these patients had 
AMI.
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of longer duration. A limit of detection well below 
15 ng/L and the cardiac specificity of cTnT is a prereq-
uisite for ruling out AMI in patients with recent onset of 
symptoms [5]. However, this gain in sensitivity for AMI 
would be at the expense of a low or very low positive 
predictive value as shown in Table  2. There is no ideal 
POCT for the diagnosis of AMI within 6  h of onset of 
symptoms [23]. However, no patient in our study had 
a history of less than 10  h until the blood sample was 
drawn. After an AMI, the hs-cTnT value may remain 
above the decision limit of ≥15  ng/L for 2  weeks [5]. 
Therefore, we included all patients with onset or aggra-
vation of symptoms during the last 7  days in order to 
detect all possible cases of AMI or UA. In a previous 
study, we found that the use of POCT-cTnT with a detec-
tion limit of 30  ng/L in primary care may occasionally 
result in missed diagnoses of UA or AMI, but as shown 
in Table 2, hs-cTnT may be a diagnostic support to find 
patients even with UA [11].
Although there are several POCT instruments 
equipped with methods to detect troponin, they all have 
methodological problems. Most methods for measuring 
troponin lack the high sensitivity of most hospital labora-
tory methods and some have problems with interfering 
substances [23, 24]. However, attempts to develop more 
sensitive POCT troponin assays have been made [25, 26]. 
The POCT-cTnT used in this study had a detection level 
of 30 ng/L according to the manufacturer’s specifications. 
However, when hs-cTnT was measured in samples drawn 
at the same time, a considerable number of patients had 
hs-cTnT levels above 30 ng/L, but failed to give positive 
results with the POCT-cTnT (Figure 1). This emphasizes 
Table 4 Follow-up of 21 patients assessed for chest pain with an initial hs-cTnT level of ≥15 ng/L but no signs of AMI or 
UA
Patients are divided into groups according to hs-cTnT level 2–3 years after the initial assessment.
Values are presented as mean ± SD or number (%) as appropriate.
a Median ± quartile deviation.
hs‑cTnT ≥15 ng/L without  
AMI or UA n = 21
hs‑cTnT after 2–3 years P value
<15 ng/L n = 7 ≥15 ng/L n = 14
Age (years) 81 ± 9 75 ± 9 83 ± 7 0.049
Male 16 (76) 5 (71) 11 (79) 1.000
Risk factors
 Current smokers 0 0 0
 Diabetes 6 (29) 2 (29) 4 (29) 1.000
 Hypertension 18 (86) 5 (71) 13 (93) 0.247
 Hypercholesterolaemia 7 (33) 3 (43) 4 (29) 0.638
Cardiovascular disease
 Angina pectoris 1 (5) 1 (14) 0 0.333
 Previous AMI 3 (14) 2 (29) 1 (7) 0.247
 Heart failure 3 (14) 1(14) 2 (14) 1.000
 Aortic valve disease 3 (14) 1 (14) 2 (14) 1.000
ECG findings
 Atrial fibrillation 8 (38) 2 (29) 6 (43) 0.656
Laboratory findings
 eGFR (mL/min) 62 ± 17 74 ± 11 56 ± 16 0.017
 NT‑proBNP (ng/L)a 440 ± 775 150 ± 338 1,245 ± 883 0.017
 Cholesterol (mmol/L) 4.5 ± 1.3 4.4 ± 1.7 4.6 ± 1.2 0.754
Symptoms and findings
 Angina pectoris or dyspnoea 3 (14) 2 (29) 1 (7) 0.247
 Length (cm) 173 ± 7 173 ± 10 173 ± 7 0.847
 Body weight (kg) 85 ± 13 85 ± 10 84 ± 15 0.889
 BMI (kg/m2) 28 ± 4 29 ± 5 28 ± 4 0.862
 Waist circumference (cm) 106 ± 11 107 ± 11 106 ± 11 0.878
 Systolic BP (mm Hg)a 120 ± 10 120 ± 2.5 130 ± 11 0.176
 Diastolic BP (mm Hg)a 70 ± 6 70 ± 7 65 ± 6 0.658
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the need for proper validation of POCT methods both in 
relation to the detection limit and clinical outcome.
Follow‑up of patients with hs‑cTnT levels >15 ng/L 
but without signs of AMI or UA
After 2–3 years, two-thirds of the 21 patients still had 
a cTnT level ≥15 ng/L. This can be compared with the 
fact that ED patients, at least 75  years old and with-
out conditions that increase cTnT, have been shown to 
have cTnT levels above the 99th percentile in 43–48% 
of cases [20, 21]. In one-third of these cases, cTnT 
levels had normalized after almost 3  years. Subclini-
cal myocardial infarctions may have been present but 
there were no signs of q-waves on the ECG at follow-
up. At the follow-up, patients with mild heart failure 
could possibly have had increased cTnT values at some 
time due to temporary infections or other causes that 
normalize without treatment [5]. There were more 
patients with atrial fibrillation, although not statisti-
cally significant, in the group with cTnT >15 ng/L. This 
is in accordance with previous studies showing that 
atrial fibrillation is associated with increased base-
line cardiac troponin values [27, 28]. It is well known 
that normal aging affects renal function and the level 
of NT-proBNP [18, 29]. However, our study group was 
too small for a multivariate analysis aiming to adjust 
eGFR and NT-proBNP for age.
Strengths and limitations
A major strength of the study is the prospective design and 
rigorous follow-up of patients, even if sent home, to evalu-
ate missed diagnoses. A limitation is the low number of 
cases of AMI and UA influencing the reliability of the sen-
sitivity and specificity calculations. However, this reflects 
the situation in Swedish primary care, where patients with 
acute chest pain symptoms are directed to emergency care 
without passing the PHC centre. A larger study population 
would probably lead to a clearer association between the 
level of hs-cTnT, atrial fibrillation and eGFR.
Potential clinical implications
The 99th percentile used to set the limit for ruling out 
using the cTnT level is based on measurements in a 
relatively young healthy population 20–71  years of age 
(median 45  years) [14]. In accordance with the results 
in this study, several authors have suggested that a 
higher limit has to be considered for patients older 
than 65–70  years [12, 20, 21], which is in line with our 
findings.
Additional clinical information could be gained if NT-
proBNP is analysed at the same time as hs-cTnT. Both 
these cardiac markers can possibly serve as tools for 
managing patients with cardiac disease in primary care 
when making the decision on whether to refer emer-
gently for hospital care or to monitor non-acute cardiac 
patients.
Conclusions
A reliable POCT hs-cTnT could become valuable in pri-
mary care if applied to patients younger than 65  years 
presenting with symptoms suggestive of AMI or UA. For 
patients older than 65–70 years a higher decision limit of 
cTnT than ≥15  ng/L should be considered. The POCT-
cTnT instrument Cobas h232 did not perform analytically 
as well as specified by the manufacturer, especially in the 
lower measuring range. This study emphasizes that before 
introducing new methods for cardiac markers in pri-
mary care, the method must be validated by independent 
researchers and clinical outcomes should be evaluated in 
a large enough, typical, primary care patient population.
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